Abstract
Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1118-1120 |
| Number of pages | 3 |
| Journal | Diabetologia |
| Volume | 44 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Blood glucose
- Blood pressure
- Cardiovascular disease
- Controlled clinical trial
- Diabetes mellitus
- Diabetic nephropathy
- Diabetic retinopathy
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Study rationale and design of ADVANCE : Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation. / Chalmers, J.; Cooper, M.; Ferrannini, E.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Liu, L.; MacMahon, S.; Mancia, G.; Marre, M.; Matthews, D.; Mogensen, C.; Neal, B.; Yu Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Woodward, M.; Collins, R.; Sandercock, P.; Sleight, P.; Holman, R.; Fulcher, G.; Pollock, C.; Celermajer, D.; Watson, J.; Harrisberg, B.; Currie, R.; Girgis, S.; Jayne, K.; Monaghan, H.; Patel, A.; Richens, A.; Gray, B.; Milne, A.; Adderkin, A.; Bak, A.; Flett, S.; De Guise, D.; Jetses, E.; Reid, J.; Stolk, R.; Wang, W.; Williams, F.; Zou, X.
In: Diabetologia, Vol. 44, No. 9, 2001, p. 1118-1120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Study rationale and design of ADVANCE
T2 - Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation
AU - Chalmers, J.
AU - Cooper, M.
AU - Ferrannini, E.
AU - Glasziou, P.
AU - Grobbee, D.
AU - Hamet, P.
AU - Harrap, S.
AU - Liu, L.
AU - MacMahon, S.
AU - Mancia, G.
AU - Marre, M.
AU - Matthews, D.
AU - Mogensen, C.
AU - Neal, B.
AU - Yu Pan, C.
AU - Poulter, N.
AU - Rodgers, A.
AU - Williams, B.
AU - Woodward, M.
AU - Collins, R.
AU - Sandercock, P.
AU - Sleight, P.
AU - Holman, R.
AU - Fulcher, G.
AU - Pollock, C.
AU - Celermajer, D.
AU - Watson, J.
AU - Harrisberg, B.
AU - Currie, R.
AU - Girgis, S.
AU - Jayne, K.
AU - Monaghan, H.
AU - Patel, A.
AU - Richens, A.
AU - Gray, B.
AU - Milne, A.
AU - Adderkin, A.
AU - Bak, A.
AU - Flett, S.
AU - De Guise, D.
AU - Jetses, E.
AU - Reid, J.
AU - Stolk, R.
AU - Wang, W.
AU - Williams, F.
AU - Zou, X.
PY - 2001
Y1 - 2001
N2 - Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.
AB - Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.
KW - Blood glucose
KW - Blood pressure
KW - Cardiovascular disease
KW - Controlled clinical trial
KW - Diabetes mellitus
KW - Diabetic nephropathy
KW - Diabetic retinopathy
UR - http://www.scopus.com/inward/record.url?scp=17944382481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17944382481&partnerID=8YFLogxK
U2 - 10.1007/s001250100612
DO - 10.1007/s001250100612
M3 - Article
C2 - 11596665
AN - SCOPUS:17944382481
VL - 44
SP - 1118
EP - 1120
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 9
ER -